EcoDrugPlus

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSDCDG00000003819
Gene Symbol: LOC114795299
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSDCDG00000021537
Gene Symbol: TOP1
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSDCDG00000029110
Gene Symbol: TOP2B
3 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSDCDG00000003993
Gene Symbol: EML4
3 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSDCDG00000026305
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSDCDG00000014920
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSDCDG00000026925
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDCDG00000023745
Gene Symbol: FYN
3 Cross references
201 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSDCDG00000033404
Gene Symbol: GPR119
1 Cross references
176 Possible Orthologues:

Gtpase Kras

Ensembl ID : ENSDCDG00000031166
Gene Symbol: LOC114767482
3 Cross references
203 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDCDG00000027892
Gene Symbol: HCK
3 Cross references
203 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSDCDG00000033348
Gene Symbol: JAK1
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).